Part D 'windfall' for pharma, report says

Hear that whistling sound past your ears? It's a Medicare Part D windfall--or so says a House committee report released yesterday. The Committee on Oversight and Government Reform looked at Part D and found that taxpayers are paying up to 30 percent more for prescription drugs under that program than under Medicaid. "Medicare Part D has given the major drug companies a taxpayer-funded windfall worth billions of dollars," Chairman Henry Waxman said.

According to the committee, drugmakers reaped $3.7 billion more off Part D meds over the past two years than they would have selling the same drugs under Medicaid. As an example, Waxman cited Bristol-Myers Squibb's Plavix sales to Part D; they garnered an additional $400 million for the company, he said.

The ranking Republican on that committee begged to differ, however. Rep. Thomas M. Davis said the cost of Part D had come in nearly 40 percent lower than original estimates.

- read the Los Angeles Times story

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.